Issue 10, 2003

Preparation and in vitro evaluation of GdDOTA-(BOM)4; a novel angiographic MRI contrast agent

Abstract

A novel Gd(III) complex, GdDOTA-(BOM)4, has been prepared by a simple three-step procedure. The complex showed high T1-relaxivity values in serum albumin solutions, blood and plasma, resulting from high affinity for serum albumin. The T1-relaxivity in plasma, 67.4 s−1 mM−1 (20 MHz, 37 °C), makes it a promising candidate for angiographic applications of MRI.

Graphical abstract: Preparation and in vitro evaluation of GdDOTA-(BOM)4; a novel angiographic MRI contrast agent

Article information

Article type
Paper
Submitted
19 Feb 2003
Accepted
31 Mar 2003
First published
10 Apr 2003

Org. Biomol. Chem., 2003,1, 1707-1710

Preparation and in vitro evaluation of GdDOTA-(BOM)4; a novel angiographic MRI contrast agent

R. Hovland, A. J. Aasen and J. Klaveness, Org. Biomol. Chem., 2003, 1, 1707 DOI: 10.1039/B301944F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements